相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。PD-1 restraint of regulatory T cell suppressive activity is critical for immune tolerance
Catherine L. Tan et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2021)
Testing Cancer Immunotherapy in a Human Immune System Mouse Model: Correlating Treatment Responses to Human Chimerism, Therapeutic Variables and Immune Cell Phenotypes
Juan A. Marin-Jimenez et al.
FRONTIERS IN IMMUNOLOGY (2021)
Final result of phase IB study of regorafenib and nivolumab in mismatch repair proficient advanced refractory colorectal cancer
R. Kim et al.
ANNALS OF ONCOLOGY (2021)
Development of an Adrenocortical Cancer Humanized Mouse Model to Characterize Anti-PD1 Effects on Tumor Microenvironment
Julie Lang et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2020)
A phase II study investigating cabozantinib in patients with refractory metastatic colorectal cancer (AGICC 17CRC01).
Aaron James Scott et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Cabozantinib in combination with atezolizumab in urothelial carcinoma previously treated with platinum-containing chemotherapy: Results from cohort 2 of the COSMIC-021 study.
Sumanta K. Pal et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Characterization of human cancer xenografts in humanized mice
Jonathan Rios-Doria et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Cabozantinib in patients with platinum-refractory metastatic urothelial carcinoma: an open-label, single-centre, phase 2 trial
Andrea B. Apolo et al.
LANCET ONCOLOGY (2020)
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer
T. Andre et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Interferon γ and Its Important Roles in Promoting and Inhibiting Spontaneous and Therapeutic Cancer Immunity
Elise Alspach et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2019)
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Brian I. Rini et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts
A. Capasso et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
CD8 T Cell Exhaustion During Chronic Viral Infection and Cancer
Laura M. McLane et al.
Annual Review of Immunology (2019)
Phase I/II study of axitinib (axi) and nivolumab (nivo) in patients with metastatic renal cell carcinoma (mRCC).
Matthew R. Zibelman et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial
Cathy Eng et al.
LANCET ONCOLOGY (2019)
Humanized mice in studying efficacy and mechanisms of PD-1-targeted cancer immunotherapy
Minan Wang et al.
FASEB JOURNAL (2018)
A Hitchhiker's guide to humanized mice: new pathways to studying viral infections
Jessica Katy Skelton et al.
IMMUNOLOGY (2018)
Cabozantinib Exhibits Potent Antitumor Activity in Colorectal Cancer Patient-Derived Tumor Xenograft Models via Autophagy and Signaling Mechanisms
Aaron J. Scott et al.
MOLECULAR CANCER THERAPEUTICS (2018)
Overview of the Mechanisms that May Contribute to the Non-Redundant Activities of Interferon-Inducible CXC Chemokine Receptor 3 Ligands
Mieke Metzemaekers et al.
FRONTIERS IN IMMUNOLOGY (2018)
Human cancer evolution in the context of a human immune system in mice
Odd L. Gammelgaard et al.
MOLECULAR ONCOLOGY (2018)
Selective expansion of myeloid and NK cells in humanized mice yields human-like vaccine responses
Florian Douam et al.
NATURE COMMUNICATIONS (2018)
A phase Ib study of safety and clinical activity of atezolizumab (A) and cobimetinib (C) in patients (pts) with metastatic colorectal cancer (mCRC).
Johanna C. Bendell et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Effective combinatorial immunotherapy for castration-resistant prostate cancer
Xin Lu et al.
NATURE (2017)
Replacing mouse BAFF with human BAFF does not improve B-cell maturation in hematopoietic humanized mice
Julie Lang et al.
BLOOD ADVANCES (2017)
Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase II IMvigor210 study
A. Necchi et al.
ANNALS OF ONCOLOGY (2017)
Infiltrating T Cells Increase IDO1 Expression in Glioblastoma and Contribute to Decreased Patient Survival
Lijie Zhai et al.
CLINICAL CANCER RESEARCH (2017)
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Stacey Bagby et al.
JOVE-JOURNAL OF VISUALIZED EXPERIMENTS (2016)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
D. T. Le et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer
Edward B. Garon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
Robert J. Mayer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Cabozantinib, a Novel c-Met Inhibitor, Inhibits Colorectal Cancer Development in a Xenograft Model
Yinggang Sun et al.
MEDICAL SCIENCE MONITOR (2015)
Potent antitumor activity of cabozantinib, a c- MET and VEGFR2 inhibitor, in a colorectal cancer patient- derived tumor explant model
Eun-Kee Song et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Dual effects of a targeted small-molecule inhibitor (cabozantinib) on immune-mediated killing of tumor cells and immune tumor microenvironment permissiveness when combined with a cancer vaccine
Anna R. Kwilas et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2014)
Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
Fotios Loupakis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Human Hemato-Lymphoid System Mice: Current Use and Future Potential for Medicine
Anthony Rongvaux et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 31 (2013)
Studies of Lymphocyte Reconstitution in a Humanized Mouse Model Reveal a Requirement of T Cells for Human B Cell Maturation
Julie Lang et al.
JOURNAL OF IMMUNOLOGY (2013)
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
Axel Grothey et al.
LANCET (2013)
Generation of hematopoietic humanized mice in the newborn BALB/c-Rag2nullIl2rγnull mouse model: A multivariable optimization approach
Julie Lang et al.
CLINICAL IMMUNOLOGY (2011)
Differentiation and Persistence of Memory CD8+ T Cells Depend on T Cell Factor 1
Xinyuan Zhou et al.
IMMUNITY (2010)
AML xenograft efficiency is significantly improved in NOD/SCID-IL2RG mice constitutively expressing human SCF, GM-CSF and IL-3
M. Wunderlich et al.
LEUKEMIA (2010)
Quantitative analysis of tumor growth rate and changes in tumor marker level: Specific growth rate versus doubling time
Esmaeil Mehrara et al.
ACTA ONCOLOGICA (2009)
Deficient mismatch repair system in patients with sporadic advanced colorectal cancer
M. Koopman et al.
BRITISH JOURNAL OF CANCER (2009)
Specific growth rate versus doubling time for quantitative characterization of tumor growth rate
Esmaeil Mehrara et al.
CANCER RESEARCH (2007)
分享论文
